University of Wisconsin researchers and collaborators recently published a feasibility study that focuses on limiting fetal growth restriction in nonhuman primates through nanoparticle injections of ...

A bill before the legislature would ensure a peaceful, pain-free life for primates no longer needed for medical testing, ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess ...

Scientists tracked tiny pieces of microplastics as they moved through the brain blood vessels of mice. Some of them became ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Inc. has seen its stock tumble to a 52-week low, touching down at $1.12. With a current market capitalization of just $93 million, the company maintains a strong liquidity position with a current ...

New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.